|Catalog No ||: ||IMG-682 |
|Contents ||: ||0.1 ml in 10 mM HEPES (pH 7.5), 150 mM NaCl, 0.1 mg/ml BSA and 50% glycerol. Adequate amount of material to conduct 10 mini Western Blots. |
|Isotype ||: ||Mouse-IgG1 |
|Clone ||: ||608 |
|Purification ||: ||Protein G Chromatography |
|Species React ||: ||Human |
|Host ||: ||Mouse || ||Application |
Western blot analysis: 1:1000-1:2000
For long-term storage –80°C is recommended, but short-term storage at –20°C is also acceptable as aliquots may be taken without freeze/thawing due to the presence of 50% glycerol.
Recommended Positive Control : T47D treated with synthetic progestin agonist R5020 (500 nM)
There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer. The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (A and B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones. Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor. Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser190 and Ser294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.
1. Clemm, D.L., Sherman, L., Boonyaratanakornkit, V., Schrader, W.T., Weigel, N.L., and Edwards, D.P.,Mol. Endocrinol., 14 (2000) 52 - 65.
2. Lin, V. C. L., Woon, C. T., Aw, S. E., Guo, C.,Endocrinology 144 (2003) 5650 -5657.